Skip to main content
OpenTrials

Clinical trial condition

Clostridium Infections

Explore clinical trials studying Clostridium Infections. Study availability and eligibility vary by location and protocol.

316 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Clostridium Infections trial results

Completed

To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children

NCT04618939

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +6 more
Locations
  • Changwon Fatima Hospital Changwon, South Korea
  • The Catholic University of Korea Daejeon St. Mary's Hospital Daejeon, South Korea
  • The Catholic University of Korea Incheon St. Mary's Hospital Incheon, South Korea
  • Asan Medical Center Seoul, South Korea
View Trial Details
Completed

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

NCT03311659

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +12 more
Locations
  • GSK Investigational Site Barnaul, Russia
  • GSK Investigational Site Gatchina, Russia
  • GSK Investigational Site Moscow, Russia
  • GSK Investigational Site Moscow, Russia
View Trial Details
Completed

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

NCT01453998

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Santo Domingo, Dominican Republic
  • GSK Investigational Site Santo Domingo, Distrito Nacional, Dominican Republic
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
View all 16 locations
View Trial Details
Completed

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site Mesa, Arizona, United States
View all 37 locations
View Trial Details
Completed

Evaluation of an Infant Immunization Encouragement Program in Nigeria

NCT03870061

Conditions
Actinomycetales Infections, Arbovirus Infections, Bacterial Infections, +55 more
Locations
  • Primary Health Care facilities across Jigawa State Various Cities, Jigawa State, Nigeria
  • Primary Health Care facilities across Katsina State Various Cities, Katsina State, Nigeria
  • Primary Health Care facilities across the Zamfara State Various Cities, Zamfara State, Nigeria
View Trial Details
Completed

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

NCT00148941

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Fairfield, California, United States
View all 24 locations
View Trial Details

Related conditions